UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42268 Andretti Acquisition Corp. II (Exact Name of Registrant as Specified in Its Charter) | Cayman Islands | 98-1792547 | | --- | --- | | ( ...

EXHIBIT 99.1 Yelp Reports Second Quarter 2025 Results Net Revenue increased by 4% year over year to a record $370 million Net Income increased by 16% year over year to $44 million, reflecting a 12% margin Adjusted EBITDA grew 10% year over year to $100 million, reflecting a 27% margin 1 Narrows range of 2025 Net Revenue outlook to $1.465 billion to $1.475 billion; and Adjusted EBITDA outlook to $350 million to $360 million 2 SAN FRANCISCO--(BUSINESS WIRE)--August 7, 2025--Yelp Inc. (NYSE: YELP), the trusted ...

Exhibit 99 RCM Technologies reported revenue of $78.2 million for the thirteen weeks ended June 28, 2025 (the current quarter), an increase of 13.0% compared to $69.2 million for the thirteen weeks ended June 29, 2024 (the comparable prior quarter). Gross profit was $22.3 million for the current quarter, an 11.4% increase compared to $20.0 million for the comparable prior quarter. The Company experienced GAAP net income of $3.8 million, or $0.50 per diluted share, for the current quarter compared to $3.8 mi ...

Century Aluminum Company Reports Second Quarter 2025 Results Chicago, August 7, 2025 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) today announced its second quarter 2025 results. Second Quarter 2025 Financial Results | $MM (except shipments and per share data) | | | | | | --- | --- | --- | --- | --- | | | Q2 2025 | | | Q1 2025 | | Aluminum shipments (tonnes) | | 175,741 | | 168,672 | | Net sales | $ | 628.1 | $ | 633.9 | | Net (loss) income attributable to Century stockholders | $ | (4.6) $ | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or ...

Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 FINANCIAL RESULTS Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of clase ...

Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 million ...

SAN DIEGO, August 7, 2025 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced its financial results for the second quarter ended June 30, 2025 and provided highlights on its clinical programs. "We continue to be encouraged by the performance of our dual CAB EpCAM x CD3 bispecific TCE, BA3182, in Phase 1 and rem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 814-00735 Portman Ridge Finance Corporation (Exact name of Registrant as specified in its charter) (State or other jurisdiction of Incorporation or organi ...

[PART I - FINANCIAL INFORMATION](index=6&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) Presents the unaudited consolidated financial statements for Q2 and H1 2025, reporting a net loss with no revenue generated Consolidated Balance Sheet Highlights | Financial Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents and investments | $271.5 million | $372.3 million | | Total Assets | $421.0 million | $527.7 million | | Total Liabilities | $66.8 million | $64.5 million | | Total Stockholders' Equity | $354.2 million | $463.2 million | Consolidated Statements of Operations Highlights | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenue | $0 | $0 | | Research and development | $42.7 million | $46.3 million | | General and administrative | $25.0 million | $27.4 million | | Restructuring | $3.5 million | $0 | | **Net Loss** | **($68.9 million)** | **($69.6 million)** | | **Net Loss Per Share** | **($0.62)** | **($0.74)** | Consolidated Cash Flow Highlights | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($104.8 million) | ($110.7 million) | | Net cash (used in) provided by investing activities | ($26.3 million) | $90.7 million | | Net cash provided by financing activities | $0.2 million | $2.7 million | [Notes to Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Provides details on accounting policies, liquidity risks, a corporate reorganization, and a clinical hold on the RP-A501 trial - Rocket is a late-stage biotechnology company developing gene therapies for rare cardiovascular and hematology disorders[32](index=32&type=chunk)[33](index=33&type=chunk)[34](index=34&type=chunk) - As of June 30, 2025, the company had an accumulated deficit of **$1.35 billion**, with cash and investments of **$271.5 million** expected to fund operations into Q2 2027[37](index=37&type=chunk) - In July 2025, the company initiated a strategic reorganization involving a **30% workforce reduction** and a restructuring charge of approximately **$3.5 million**[40](index=40&type=chunk)[110](index=110&type=chunk)[111](index=111&type=chunk) - In May 2025, the FDA placed a clinical hold on the Phase 2 trial for RP-A501 for Danon disease following a Serious Adverse Event (SAE)[39](index=39&type=chunk)[54](index=54&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Details management's perspective on financial condition, operational results, a strategic reorganization, and key clinical updates [Overview and Strategy](index=25&type=section&id=Overview%20and%20Strategy) Outlines the strategic shift to prioritize the AAV cardiovascular platform, reduce operating expenses, and seek external partnerships - In July 2025, the company announced a strategic corporate reorganization to focus resources on its AAV cardiovascular platform and respond to the CRL for KRESLADI™[119](index=119&type=chunk) - The restructuring included a **30% workforce reduction** and is expected to reduce 12-month operating expenses by nearly **25%**[119](index=119&type=chunk) - The company is actively exploring external partnership options for its Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301) programs[173](index=173&type=chunk)[179](index=179&type=chunk) [Pipeline Overview](index=27&type=section&id=Pipeline%20Overview) Reviews the company's pipeline, highlighting the clinical hold on RP-A501 and the Complete Response Letter for KRESLADI™ - The FDA placed the Phase 2 pivotal trial for RP-A501 (Danon disease) on clinical hold on May 23, 2025, after a patient experienced a Serious Adverse Event (SAE)[151](index=151&type=chunk)[152](index=152&type=chunk) - In June 2024, the FDA issued a Complete Response Letter (CRL) for the KRESLADI™ (RP-L201) BLA for LAD-I, requesting additional CMC information[166](index=166&type=chunk) - For the Fanconi Anemia program (RP-L102), an MAA was accepted by the EMA, but the company is now seeking external partners for regulatory filings[173](index=173&type=chunk) [Results of Operations](index=38&type=section&id=Results%20of%20Operations) Compares financial results for the six months ended June 30, 2025 and 2024, noting changes in R&D and G&A expenses Comparison of Operations | Metric | Six Months Ended June 30, 2025 ($M) | Six Months Ended June 30, 2024 ($M) | Change ($M) | | :--- | :--- | :--- | :--- | | R&D Expenses | 78.6 | 91.6 | (13.0) | | G&A Expenses | 53.5 | 49.5 | 4.0 | | Restructuring | 3.5 | 0.0 | 3.5 | | **Net Loss** | **(130.3)** | **(131.7)** | **1.4** | - The decrease in R&D expenses for the six-month period was primarily driven by lower manufacturing costs (**$4.8M**), professional fees (**$3.6M**), and a **$2.7M** CIRM grant[207](index=207&type=chunk) - The increase in G&A expenses for the six-month period was primarily driven by a **$4.3 million increase** in legal expenses[208](index=208&type=chunk) [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) Assesses the company's financial position, including its cash balance, accumulated deficit, and projected cash runway into Q2 2027 - As of June 30, 2025, the company had **$271.5 million** in cash, cash equivalents, and investments and an accumulated deficit of **$1.35 billion**[213](index=213&type=chunk) - The company believes its current financial resources are sufficient to fund operating expenses and capital expenditure requirements into the **second quarter of 2027**[213](index=213&type=chunk) - Net cash used in operating activities was **$104.8 million** for the six months ended June 30, 2025, compared to $110.7 million for the same period in 2024[215](index=215&type=chunk)[216](index=216&type=chunk)[217](index=217&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Discusses the company's exposure to interest rate risk on its investment portfolio and the potential impact of rate changes - The company's primary market risk is interest rate sensitivity on its **$271.5 million** portfolio of cash, cash equivalents, and investments as of June 30, 2025[223](index=223&type=chunk) - A hypothetical uniform **100-basis-point increase** in interest rates would result in a decline of **$0.7 million** in the net fair value of the company's investments[224](index=224&type=chunk) [Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) Confirms the effectiveness of the company's disclosure controls and procedures as of the end of the reporting period - Management concluded that the company's disclosure controls and procedures were **effective** as of June 30, 2025[226](index=226&type=chunk) - There were **no material changes** to the company's internal control over financial reporting during the quarter[229](index=229&type=chunk) [PART II - OTHER INFORMATION](index=43&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Legal Proceedings](index=43&type=section&id=Item%201.%20Legal%20Proceedings) Details the settlement of litigation with Lexeo Therapeutics and the filing of two new securities class action lawsuits - In June 2025, the company settled litigation with Lexeo Therapeutics, Inc, with the financial impact being **not material**[230](index=230&type=chunk)[231](index=231&type=chunk) - Two securities class action lawsuits were filed against the company in June and July 2025 related to public statements about the Phase 2 clinical trial for RP-A501[232](index=232&type=chunk) [Risk Factors](index=43&type=section&id=Item%201A.%20Risk%20Factors) Highlights new risks related to securities litigation costs and the potential challenges of the recent strategic restructuring - A new risk factor is the potential for substantial costs and diversion of management resources due to recently filed securities class action lawsuits[235](index=235&type=chunk)[236](index=236&type=chunk) - The company's strategic restructuring may not achieve anticipated savings and could lead to unforeseen difficulties, unexpected costs, or attrition[238](index=238&type=chunk)[239](index=239&type=chunk) [Other Information (Items 2-6)](index=44&type=section&id=Items%202-6.%20Other%20Information) Covers standard disclosures including unregistered equity sales, senior securities defaults, and Rule 10b5-1 trading plans - There were no unregistered sales of equity securities or defaults upon senior securities during the period[240](index=240&type=chunk)[241](index=241&type=chunk) - No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the three months ended June 30, 2025[243](index=243&type=chunk)